News from chemomab ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 04, 2022, 07:00 ET Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development Operations

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative...

Dec 20, 2021, 08:00 ET Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative...

Nov 12, 2021, 07:00 ET Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative...

Nov 10, 2021, 07:00 ET Chemomab Announces Poster Presentation at AASLD's The Liver Meeting® 2021

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative...

Nov 09, 2021, 07:00 ET Chemomab to Present at Stifel 2021 Virtual Healthcare Conference

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative...

Oct 26, 2021, 08:53 ET Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative...

Sep 27, 2021, 07:00 ET Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative...

Sep 02, 2021, 07:00 ET Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for...

Sep 01, 2021, 07:18 ET Chemomab to Participate in Upcoming September Investor Conferences

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for...

Aug 13, 2021, 08:00 ET Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for...

Jun 23, 2021, 08:30 ET Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for...

Jun 10, 2021, 07:00 ET Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL)

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for...

May 13, 2021, 09:25 ET Chemomab Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for...

May 12, 2021, 07:00 ET Chemomab to Present at Oppenheimer's Virtual Rare and Orphan Disease Summit

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for...

Apr 26, 2021, 06:30 ET Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for...

Mar 29, 2021, 09:00 ET Chemomab Announces Four New Appointments to the Board of Directors and Completion of PIPE Financing

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for...

Mar 16, 2021, 16:45 ET Chemomab Completes Merger with Anchiano Therapeutics

Chemomab Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases...

Feb 02, 2021, 09:32 ET Chemomab Announces First Patient Enrolled in Phase IIa Study of CM-101 for the Treatment of Patients with Primary Sclerosing Cholangitis

Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today ...

Jan 05, 2021, 08:30 ET Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients

Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today ...

Oct 19, 2020, 10:00 ET Chemomab Announces Late-Breaking Presentation of CM-101 First Evidence of Anti-Fibrotic Activity in NAFLD Patients at the AASLD's The Liver Meeting Digital Experience™ 2020

Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today ...

Aug 26, 2020, 07:00 ET Chemomab Receives European Orphan Drug Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today ...

Jul 21, 2020, 09:00 ET Chemomab Receives Regulatory Approval to Commence a Phase II Clinical Trial for CM-101 as Treatment of Primary Sclerosing Cholangitis

Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today ...

Feb 19, 2020, 09:00 ET ChemomAb Ltd. Announces Issuance of Composition of Matter Patent for CM-101 and Reinforces its IP Portfolio

ChemomAb Ltd., a clinical-stage biotech company focusing on development of targeted innovative therapeutics for fibrosis-related diseases with great...